학술논문

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.
Document Type
Article
Source
NPJ Vaccines; 3/29/2024, Vol. 9 Issue 1, p1-11, 11p
Subject
EBOLA virus
EBOLA virus disease
VACCINIA
VACCINES
VIRUS diseases
ANTIBODY formation
Language
ISSN
20590105
Abstract
Copyright of NPJ Vaccines is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)